
The FDA approved asundexian (Sunharbo) with antiplatelet therapy to reduce recurrent stroke risk after noncardioembolic stroke or high-risk TIA.
Coverage of our peer-reviewed research in the healthcare and mainstream press.
The Gainesville Sun depicted the stories of patients with Parkinson’s disease and their family members in an article titled “






